0.10Open0.10Pre Close0 Volume462 Open Interest45.00Strike Price0.00Turnover349.54%IV132.23%PremiumApr 17, 2025Expiry Date0.00Intrinsic Value100Multiplier5DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.0358Delta0.0097Gamma194.20Leverage Ratio-0.0520Theta0.0001Rho6.94Eff Leverage0.0018Vega
Apellis Pharmaceuticals Stock Discussion
Breakthrough: EMPAVELI Scores Priority FDA Review After 68% Disease Reduction in Rare Kidney Disorders
Breakthrough for Rare Kidney Diseases: EMA Reviews First Potential Treatment Following 68% Disease Reduction
finally moving
$Moderna (MRNA.US)$ $Apellis Pharmaceuticals (APLS.US)$ $Clover Health (CLOV.US)$
$Emergent BioSolutions (EBS.US)$
$Novocure (NVCR.US)$
No comment yet